Elanco Animal Health Enters Material Agreement

TL;DR

Elanco just signed a big deal, expect financial moves.

AI Summary

Elanco Animal Health Incorporated entered into a material definitive agreement on June 25, 2025. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The report includes financial statements and exhibits.

Why It Matters

This filing signals a significant new agreement for Elanco Animal Health, potentially impacting its financial obligations and future business operations.

Risk Assessment

Risk Level: medium — Material definitive agreements and new financial obligations can introduce unforeseen risks and opportunities for a company.

Key Players & Entities

• Elanco Animal Health Incorporated (company) — Registrant
• June 25, 2025 (date) — Date of Earliest Event Reported

FAQ

From the Filing

0001104659-25-063027.txt : 20250626 0001104659-25-063027.hdr.sgml : 20250626 20250626160132 ACCESSION NUMBER: 0001104659-25-063027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250625 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250626 DATE AS OF CHANGE: 20250626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 251080302 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm2518758d1_8k.htm FORM 8-K false 0001739104 0001739104 2025-06-25 2025-06-25 0001739104 us-gaap:CommonStockMember 2025-06-25 2025-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION Washington , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): June 25, 2025   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Not Applicable (Former Name or Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨   Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 1.01 Entry into a Material Definitive Agreement.   On June 25, 2025, Elanco Animal Health Incorporated (the “Company”), solely in its role as performance guarantor, Elanco SPEAR LLC, as Borrower (the “Borrower”), and Elanco US Inc., as servicer (“Elanco US”), entered into a First Amendment to its Receivables Loan Agreement (as amended, the “Agreement”) with Coö